Ensaio em fase de recrutamento = ; Ensaio a decorrer = ; Financiado por um membro do IRDiRC = ; Membro de uma ERN =

Ensaio (s) clínico (s) nacional (is)

ALEMANHA

Thüringen
JENA

An open label phase II study of the combination of Imatinib and Lonafarnib in patients with CML in chronic phase and absence of good molecular remission - DE

Universitätsklinikum Jena

Klinik für Innere Medizin II - Abteilung Hämatologie und Internistische Onkologie

Mais detalhes

ESPANHA

Cataluña
BARCELONA

D-LIVR: A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy [...] in Patients Chronically Infected with Hepatitis Delta Virus [...] - ES

Hospital Universitari Vall d'Hebron

Servicio de Hepatología

Mais detalhes

ESPANHA

Comunidad Valenciana
VALENCIA

D-LIVR: A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy [...] in Patients Chronically Infected with Hepatitis Delta Virus [...] - ES

Hospital Universitario y Politécnico La Fe

Servicio de Hepatología

Mais detalhes

ESPANHA

Madrid
MADRID

D-LIVR: A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy [...] in Patients Chronically Infected with Hepatitis Delta Virus [...] - ES

Hospital Universitario La Paz

Servicio de Aparato Digestivo

Mais detalhes